Esophagitis News and Research

RSS

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects.

18 Mar 2015

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.

24 Feb 2015

Ohio State allergy specialists study, learn more about eosinophilic esophagitis

Its name is daunting. It's the hottest topic among allergy experts. It's showing up more and doctors don't yet know why. Allergy specialists at The Ohio State University Wexner Medical Center are seeing more people with eosinophilic esophagitis (EoE), an inflammatory response in the esophagus that makes it hard to swallow food.

9 Feb 2015

Gastroenterology publishes landmark data from RESPECT study of Transoral Incisionless Fundoplication procedure

EndoGastric Solutions announces that Gastroenterology, the official journal of the American Gastroenterological Association Institute and the most prominent journal in the field of gastrointestinal disease, has published landmark data from the first-ever blinded, randomized, sham- and placebo-controlled clinical study of the Transoral Incisionless Fundoplication (TIF) procedure.

22 Jan 2015

Oral budesonide suspension offers hope for pediatric patients with EoE

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

19 Dec 2014

Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC

Research suggests that treatment with cisplatin plus S-1 together with thoracic radiotherapy is relatively efficacious and tolerable in patients with locally advanced non-small-cell lung cancer.

11 Dec 2014

Scientists identify four new genes associated with severe food allergy

Scientists have identified four new genes associated with the severe food allergy eosinophilic esophagitis (EoE). Because the genes appear to have roles in other allergic diseases and in inflammation, the findings may point toward potential new treatments for EoE.

21 Nov 2014

CHOP joins CEGIR to advance treatment of eosinophilic disorders

The Children's Hospital of Philadelphia has joined a new consortium announced today by the National Institutes of Health to advance the treatment of chronic inflammatory diseases called eosinophilic disorders.

9 Oct 2014

Pediatric specialist in EGIDs helps lead $6.25 million NIH clinical research project

A pediatric specialist in eosinophilic gastrointestinal diseases (EGIDs) at the University of Colorado School of Medicine and Children's Hospital Colorado will help lead a five-year, $6.25 million clinical research project recently funded by the National Institutes of Health.

9 Oct 2014

Understanding ways to treat, cure eosinophilic gastritis

Investigators at Cincinnati Children's Hospital Medical Center have published the first study to extensively characterize eosinophilic gastritis (EG).

24 Sep 2014

Researchers say that environment plays much stronger role than genetics in eosinophilic esophagitis

Researchers have found that environment has a much stronger role than genetics in eosinophilic esophagitis (EoE), a severe, often painful food allergy that renders children unable to eat a wide variety of foods.

23 Sep 2014

Study: Dietary elimination is successful method of treatment for adults with EoE

Dietary elimination is a successful method of treatment for adults with eosinophilic esophagitis (EoE), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

21 Jul 2014

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils.

19 Jul 2014

NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

Scientists funded by the National Institutes of Health have identified genetic markers associated with eosinophilic esophagitis (EoE), an inflammatory disease characterized by high levels of immune cells called eosinophils in the esophagus.

15 Jul 2014

New research opens up potential new therapeutic targets for hard-to-treat food allergy

New research in Nature Genetics identifies a novel genetic and molecular pathway in the esophagus that causes eosinophillic esophagitis (EoE), opening up potential new therapeutic strategies for an enigmatic and hard-to-treat food allergy.

14 Jul 2014

RD Biomed announces Chinese distribution agreement for reflux diagnostic tool Peptest

RD Biomed, the Yorkshire medical technology company, has announced a Chinese distribution agreement for its world-leading reflux diagnostic tool Peptest.

8 Jul 2014

C-section delivery, early antibiotic treatment linked to eosinophilic esophagitis in children

Children delivered by cesarean section and those given antibiotics during early infancy appear more prone to developing allergic inflammation of the esophagus — the muscular tube that connects the mouth to the stomach — according to results of a study by investigators from the Johns Hopkins Children’s Center and Harvard Medical School.

13 May 2014

Access provides update on new formulation of anti-inflammatory drug amlexanox

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard™, for the treatment of inflammatory and ulcerative conditions of the esophagus.

8 Apr 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).